Drugs / Hydroxyzine
Hydroxyzine
also known as
Atarax · Hydroxyzine HCL · Alamon · Atarax dihydrochloride · Ataraxoid · Aterax · Atranine a · Durrax · +12 more
Small molecule targets HRH1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ATARAX | — | 1956-04-12 | fda.gov ↗ |
Trials 14 · a red edge is where a trial was stopped
195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00332163 | Apr 2006 → Jan 2008 | colorectal cancer, exanthem, toxic dermatosis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT01675986 | ? → Nov 2014 | anxiety | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT05737511 | Dec 2023 → Dec 2026 expected | panic disorder | Sultan Qaboos University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04184141 | Dec 2019 → Jun 2020 | — | Istanbul Medeniyet University | Unknown | No outcome recorded |
| Phase 4 | NCT04188106 | Jun → Dec 2019 | sleep disorder | Rose Research Center, LLC | Completed | No outcome recorded |
| Phase 4 | NCT03324828 | Nov 2017 → May 2020 | anxiety | Hospital San Carlos, Madrid | Terminated | No outcome recorded |
| Phase 4 | NCT01372670 | Jan 2012 → Apr 2013 | anxiety disorder, eating disorder | HealthPartners Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT01250652 | Mar 2011 → Feb 2013 | chronic urticaria | Association Asthma, Bulgaria | Completed | No outcome recorded |
| Phase 4 | NCT01151696 | May 2010 → Sep 2013 | — | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 4 | NCT00162786 | May → Nov 2005 | — | J. Uriach and Company | Terminated | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05492812 | Jan → Dec 2021 | — | Suleyman Demirel University | Completed | No outcome recorded |
| — | NCT01501591 | Nov 2012 → Oct 2015 | — | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT00661674 | Apr → Aug 2008 | substance-related disorder | Stanford University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 16 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05680584 Comparator | Feb 2023 → Jan 2024 | anxiety | Minia University | Unknown | No outcome recorded |
| Phase 1 | NCT02797522 Background | Jun → Nov 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02858310 Background | Jan 2017 → Jul 2025 | cervical intraepithelial neoplasia, human papilloma virus infection, in situ carcinoma, vulvar neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07031206 Background | Jul 2025 → May 2026 overdue | anxiety | The University of Texas Health Science Center, Houston | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02738008 Background | Mar → Dec 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02604212 Background | Nov 2015 → Dec 2016 | hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02604199 Background | Sep 2015 → Jan 2017 | chronic hepatitis B virus infection | Arrowhead Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00260481 Comparator | Jan 2006 → Jun 2008 | drug dependence, substance abuse | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05126459 Background | Feb 2022 → Apr 2023 | anxiety, dental caries | Loma Linda University | Completed | No outcome recorded |
| Phase 3 | NCT03808805 Comparator | Apr 2019 → Sep 2023 | aquagenic pruritus, myeloproliferative neoplasm | University Hospital, Brest | Completed | No outcome recorded |
| Phase 3 | NCT03728894 Comparator | Nov 2018 → Jan 2019 | — | Latakia University | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT04068948 Background | Jun 2019 → Dec 2022 | dental caries | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT01496911 Comparator | Apr → Oct 2012 | — | Utrecht Institute for Pharmaceutical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01055236 Comparator | Aug 2007 → Oct 2008 | — | Mahidol University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05224167 Comparator | Mar → Jun 2022 | — | Mongi Slim Hospital | Unknown | No outcome recorded |
| — | NCT00570388 Comparator | Mar 2007 → Sep 2008 | alcohol dependence | Institute of Addiction Medicine | Unknown | No outcome recorded |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydroxyzine | “The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg.” NCT02604212 ↗28“pre-treatment with hydroxyzine (50mg) followed by placebo medications administered both orally and through infusion, as well as a second dose of hydroxyzine (50mg)” NCT00260481 ↗ “Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion.” NCT00570388 ↗ “would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg.” NCT02604199 ↗ “would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg.” NCT02738008 ↗ “Hydroxyzine (1.5- 2mg/kg) + Meperidine (1.5 -2 mg/kg) + Midazolam (0.5- 0.75 mg/kg)” NCT05126459 ↗ “the first received hydroxyzine (25 mg) described as hydroxyzine or placebo” PMID 27899067 ↗ Nov 2016 “topical antihistamine or oral antihistamine (hydroxyzine)” NCT00332163 ↗ “hydroxyzine 50 mg PO” NCT02797522 ↗ |
| Known as | Alamon | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Atarax | “Groups HYDROXYZINE : 75 mg d'ATARAX®” NCT01675986 ↗1“Atarax (Hydroxyzine)” NCT01151696 ↗ |
| Known as | Atarax dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Ataraxoid | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Aterax | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Atranine a | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Durrax | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Hidroxizina | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Hy-pam "25" | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Hydroxyzine dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Hydroxyzine HCL | “Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion.” NCT00570388 ↗ |
| Known as | HYDROXYZINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Marex | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | NSC-169188 | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Orgatrax | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Tran-q | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Tranquizine | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | U.c.b-4492 | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Ucerax | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Known as | Vistaril | ChEMBL registry synonym — accepted as the source's own label CHEMBL896 ↗ |
| Action | Inhibit | “Histamine H1 receptor antagonist” CHEMBL896 ↗1“antagonizes H1 receptor” NCT01055236 ↗ |
| Modality | Small molecule | — CHEMBL896 ↗ |
| Route | Oral | “patients will again take 50mg of hydroxyzine orally” NCT00260481 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL896 ↗ |